Literature DB >> 15818527

[The direct costs of depressive disorders in Germany].

Susanne Friemel1, Sebastian Bernert, Matthias C Angermeyer, Hans-Helmut König.   

Abstract

OBJECTIVE: The purpose of this study was to estimate the direct costs of depression in Germany from the social perspective.
METHODS: The data came from the European Study of the Epidemiology of Mental Disorders (ESEMeD), in which a representative sample of 3555 non-institutionalised adults aged 18 years or older was interviewed in Germany. Using the most recent version of the Composite International Diagnostic Interview (WMH-CIDI), 131 persons with a 12-month prevalence of major depression, minor depression and dysthymia were identified. These patients reported their mental health care consumption of the last 12 months retrospectively, which was valued by prices of 2002.
RESULTS: The average direct costs for treating depressive disorders were 686 EUR per patient and year. The total direct costs of depression in Germany was estimated at approximately 1.6 billion EUR.
CONCLUSIONS: Because the sample was restricted to the non-institutionalised population, calculated costs may be underestimated. The costs per inhabitant in Germany exceed those reported by studies from the United Kingdom but are lower than those reported for the USA.

Entities:  

Mesh:

Year:  2005        PMID: 15818527     DOI: 10.1055/s-2004-834611

Source DB:  PubMed          Journal:  Psychiatr Prax        ISSN: 0303-4259


  8 in total

Review 1.  Mental health care in Germany: current state and trends.

Authors:  Hans Joachim Salize; Wulf Rössler; Thomas Becker
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-03       Impact factor: 5.270

2.  Who receives depression-specific treatment? A secondary data-based analysis of outpatient care received by over 780,000 statutory health-insured individuals diagnosed with depression.

Authors:  Stefanie Boenisch; Rueya-Daniela Kocalevent; Herbert Matschinger; Roland Mergl; Claudia Wimmer-Brunauer; Martin Tauscher; Dietmar Kramer; Ulrich Hegerl; Anke Bramesfeld
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2011-02-25       Impact factor: 4.328

3.  Who is treated, and how, for depression? An analysis of statutory health insurance data in Germany.

Authors:  Anke Bramesfeld; Thomas Grobe; Friedrich Wilhelm Schwartz
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-06-27       Impact factor: 4.328

4.  Resource utilisation and costs of depressive patients in Germany: results from the primary care monitoring for depressive patients trial.

Authors:  Christian Krauth; Jona T Stahmeyer; Juliana J Petersen; Antje Freytag; Ferdinand M Gerlach; Jochen Gensichen
Journal:  Depress Res Treat       Date:  2014-09-09

5.  A retrospective cost-analysis of additional homeopathic treatment in Germany: Long-term economic outcomes.

Authors:  Julia K Ostermann; Claudia M Witt; Thomas Reinhold
Journal:  PLoS One       Date:  2017-09-15       Impact factor: 3.240

6.  Health economic evaluation of a web-based intervention for depression: the EVIDENT-trial, a randomized controlled study.

Authors:  Viola Gräfe; Thomas Berger; Martin Hautzinger; Fritz Hohagen; Wolfgang Lutz; Björn Meyer; Steffen Moritz; Matthias Rose; Johanna Schröder; Christina Späth; Jan Philipp Klein; Wolfgang Greiner
Journal:  Health Econ Rev       Date:  2019-06-07

7.  The excess economic burden of mental disorders: findings from a cross-sectional prevalence survey in Austria.

Authors:  Agata Łaszewska; Johannes Wancata; Rebecca Jahn; Judit Simon
Journal:  Eur J Health Econ       Date:  2020-05-26

8.  Estimation of Input Costs for a Markov Model in a German Health Economic Evaluation of Newer Antidepressants.

Authors:  Astrid Seidl; Marion Danner; Christoph J Wagner; Frank G Sandmann; Gaby Sroczynski; Heidi Stürzlinger; Johannes Zsifkovits; Anja Schwalm; Stefan K Lhachimi; Uwe Siebert; Andreas Gerber-Grote
Journal:  MDM Policy Pract       Date:  2018-01-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.